Search Results

You are looking at 31 - 40 of 104 items for

  • Abstract: Autoimmune x
  • Abstract: Inflammation x
  • Abstract: Late effects of cancer treatment x
  • Abstract: Cognition x
Clear All Modify Search
T L C Wolters Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

Search for other papers by T L C Wolters in
Google Scholar
PubMed
Close
,
C D C C van der Heijden Division of Experimental Internal Medicine, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Division of Vascular Medicine, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

Search for other papers by C D C C van der Heijden in
Google Scholar
PubMed
Close
,
N van Leeuwen Department of Physiology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

Search for other papers by N van Leeuwen in
Google Scholar
PubMed
Close
,
B T P Hijmans-Kersten Department of Physiology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

Search for other papers by B T P Hijmans-Kersten in
Google Scholar
PubMed
Close
,
M G Netea Division of Experimental Internal Medicine, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

Search for other papers by M G Netea in
Google Scholar
PubMed
Close
,
J W A Smit Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

Search for other papers by J W A Smit in
Google Scholar
PubMed
Close
,
D H J Thijssen Department of Physiology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK

Search for other papers by D H J Thijssen in
Google Scholar
PubMed
Close
,
A R M M Hermus Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

Search for other papers by A R M M Hermus in
Google Scholar
PubMed
Close
,
N P Riksen Division of Vascular Medicine, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

Search for other papers by N P Riksen in
Google Scholar
PubMed
Close
, and
R T Netea-Maier Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

Search for other papers by R T Netea-Maier in
Google Scholar
PubMed
Close

Objective

Acromegaly is characterized by an excess of growth hormone (GH) and insulin-like growth factor 1 (IGF1). Cardiovascular disease (CVD) risk factors are common in acromegaly and often persist after treatment. Both acute and long-lasting pro-inflammatory effects have been attributed to IGF1. Therefore, we hypothesized that inflammation persists in treated acromegaly and may contribute to CVD risk.

Methods

In this cross-sectional study, we assessed cardiovascular structure and function, and inflammatory parameters in treated acromegaly patients. Immune cell populations and inflammatory markers were assessed in peripheral blood from 71 treated acromegaly patients (with controlled or uncontrolled disease) and 41 matched controls. Whole blood (WB) was stimulated with Toll-like receptor ligands. In a subgroup of 21 controls and 33 patients with controlled disease, vascular ultrasound measurements were performed.

Results

Leukocyte counts were lower in patients with controlled acromegaly compared to patients with uncontrolled acromegaly and controls. Circulating IL18 concentrations were lower in patients; concentrations of other inflammatory mediators were comparable with controls. In stimulated WB, cytokine production was skewed toward inflammation in patients, most pronounced in those with uncontrolled disease. Vascular measurements in controlled patients showed endothelial dysfunction as indicated by a lower flow-mediated dilatation/nitroglycerine-mediated dilatation ratio. Surprisingly, pulse wave analysis and pulse wave velocity, both markers of endothelial dysfunction, were lower in patients, whereas intima-media thickness did not differ.

Conclusions

Despite treatment, acromegaly patients display persistent inflammatory changes and endothelial dysfunction, which may contribute to CVD risk and development of CVD.

Open access
Fernando Aprile-Garcia Instituto de Investigación en Biomedicina de Buenos Aires – CONICET, Departamento de Fisiología, Partner Institute of the Max Planck Society, Buenos Aires, Argentina
Instituto de Investigación en Biomedicina de Buenos Aires – CONICET, Departamento de Fisiología, Partner Institute of the Max Planck Society, Buenos Aires, Argentina

Search for other papers by Fernando Aprile-Garcia in
Google Scholar
PubMed
Close
,
María Antunica-Noguerol Instituto de Investigación en Biomedicina de Buenos Aires – CONICET, Departamento de Fisiología, Partner Institute of the Max Planck Society, Buenos Aires, Argentina
Instituto de Investigación en Biomedicina de Buenos Aires – CONICET, Departamento de Fisiología, Partner Institute of the Max Planck Society, Buenos Aires, Argentina

Search for other papers by María Antunica-Noguerol in
Google Scholar
PubMed
Close
,
Maia Ludmila Budziñski Instituto de Investigación en Biomedicina de Buenos Aires – CONICET, Departamento de Fisiología, Partner Institute of the Max Planck Society, Buenos Aires, Argentina

Search for other papers by Maia Ludmila Budziñski in
Google Scholar
PubMed
Close
,
Ana C Liberman Instituto de Investigación en Biomedicina de Buenos Aires – CONICET, Departamento de Fisiología, Partner Institute of the Max Planck Society, Buenos Aires, Argentina

Search for other papers by Ana C Liberman in
Google Scholar
PubMed
Close
, and
Eduardo Arzt Instituto de Investigación en Biomedicina de Buenos Aires – CONICET, Departamento de Fisiología, Partner Institute of the Max Planck Society, Buenos Aires, Argentina
Instituto de Investigación en Biomedicina de Buenos Aires – CONICET, Departamento de Fisiología, Partner Institute of the Max Planck Society, Buenos Aires, Argentina

Search for other papers by Eduardo Arzt in
Google Scholar
PubMed
Close

Inflammatory responses are elicited after injury, involving release of inflammatory mediators that ultimately lead, at the molecular level, to the activation of specific transcription factors (TFs; mainly activator protein 1 and nuclear factor-κB). These TFs propagate inflammation by inducing the expression of cytokines and chemokines. The neuroendocrine system has a determinant role in the maintenance of homeostasis, to avoid exacerbated inflammatory responses. Glucocorticoids (GCs) are the key neuroendocrine regulators of the inflammatory response. In this study, we describe the molecular mechanisms involved in the interplay between inflammatory cytokines, the neuroendocrine axis and GCs necessary for the control of inflammation. Targeting and modulation of the glucocorticoid receptor (GR) and its activity is a common therapeutic strategy to reduce pathological signaling. Poly (ADP-ribose) polymerase 1 (PARP1) is an enzyme that catalyzes the addition of PAR on target proteins, a post-translational modification termed PARylation. PARP1 has a central role in transcriptional regulation of inflammatory mediators, both in neuroendocrine tumors and in CNS cells. It is also involved in modulation of several nuclear receptors. Therefore, PARP1 and GR share common inflammatory pathways with antagonic roles in the control of inflammatory processes, which are crucial for the effective maintenance of homeostasis.

Open access
Fei Wu Department of Nuclear Medicine, Yancheng City No. 1 People’s Hospital, Yancheng, China
Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, China

Search for other papers by Fei Wu in
Google Scholar
PubMed
Close
,
Chaoming Mao Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, China

Search for other papers by Chaoming Mao in
Google Scholar
PubMed
Close
,
Xiao Mou Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, China

Search for other papers by Xiao Mou in
Google Scholar
PubMed
Close
,
Chengcheng Xu Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, China

Search for other papers by Chengcheng Xu in
Google Scholar
PubMed
Close
,
Tingting Zheng Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, China

Search for other papers by Tingting Zheng in
Google Scholar
PubMed
Close
,
Ling Bu Department of Clinical Medicine, Jiangsu Health Vocational College, Nanjing, China

Search for other papers by Ling Bu in
Google Scholar
PubMed
Close
,
Xuan Luo Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, China

Search for other papers by Xuan Luo in
Google Scholar
PubMed
Close
,
Qingyan Lu Department of Laboratory Medicine, Xuzhou Central Hospital, Xuzhou, China

Search for other papers by Qingyan Lu in
Google Scholar
PubMed
Close
, and
Xuefeng Wang Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, China

Search for other papers by Xuefeng Wang in
Google Scholar
PubMed
Close

Hashimoto’s thyroiditis (HT) is a very common organ-specific autoimmune disease characterized by lymphocyte infiltration and the destruction of thyroid follicular cells (TFCs), in which IFN-γ and chemokines play pivotal roles. Moreover, β-catenin has been implicated in the regulation of T cell infiltration. However, whether β-catenin is involved in Hashimoto’s thyroiditis is unknown. Here, we examined β-catenin expression in thyroid tissues and investigated its role in the pathogenesis of HT. The results showed that β-catenin expression was markedly reduced in the thyroid tissues of HT patients; more importantly, IFN-γ treatment markedly reduced the expression of β-catenin and was accompanied by the secretion of chemokines such as CCL5, CXCL16, GRO-β, and GRO-γ in TFCs in vitro, which was attributed to GSK-3β/β-catenin signaling pathway activation. Collectively, the decreased expression of β-catenin might contribute to IFNγ-induced chemokine secretion and lymphocyte infiltration in the development of HT.

Open access
Mírian Romitti Thyroid Unit, Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

Search for other papers by Mírian Romitti in
Google Scholar
PubMed
Close
,
Vitor C Fabris Gynecological Endocrinology Unit, Endocrine Division, Hospital de Clínicas de Porto Alegre, and Department of Physiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

Search for other papers by Vitor C Fabris in
Google Scholar
PubMed
Close
,
Patricia K Ziegelmann Postgraduate Program in Epidemiology and Department of Statistics, Institute of Mathematics, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

Search for other papers by Patricia K Ziegelmann in
Google Scholar
PubMed
Close
,
Ana Luiza Maia Thyroid Unit, Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

Search for other papers by Ana Luiza Maia in
Google Scholar
PubMed
Close
, and
Poli Mara Spritzer Gynecological Endocrinology Unit, Endocrine Division, Hospital de Clínicas de Porto Alegre, and Department of Physiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

Search for other papers by Poli Mara Spritzer in
Google Scholar
PubMed
Close

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder affecting women of reproductive age. PCOS has been associated with distinct metabolic and cardiovascular diseases and with autoimmune conditions, predominantly autoimmune thyroid disease (AITD). AITD has been reported in 18–40% of PCOS women, depending on PCOS diagnostic criteria and ethnicity. The aim of this systematic review and meta-analysis was to summarize the available evidence regarding the likelihood of women with PCOS also having AITD in comparison to a reference group of non-PCOS women. We systematically searched EMBASE and MEDLINE for non-interventional case control, cross-sectional or cohort studies published until August 2017. The Ottawa–Newcastle Scale was used to assess the methodological quality of studies. Statistical meta-analysis was performed with R. Thirteen studies were selected for the present analysis, including 1210 women diagnosed with PCOS and 987 healthy controls. AITD was observed in 26.03 and 9.72% of PCOS and control groups respectively. A significant association was detected between PCOS and chance of AITD (OR = 3.27, 95% CI 2.32–4.63). Notably, after geographical stratification, the higher risk of AITD in PCOS women persisted for Asians (OR = 4.56, 95% CI 2.47–8.43), Europeans (OR = 3.27, 95% CI 2.07–5.15) and South Americans (OR = 1.86, 95% CI 1.05–3.29). AIDT is a frequent condition in PCOS patients and might affect thyroid function. Thus, screening for thyroid function and thyroid-specific autoantibodies should be considered in patients with PCOS even in the absence of overt symptoms. This systematic review and meta-analysis is registered in PROSPERO under number CRD42017079676.

Open access
Jia Liu Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Search for other papers by Jia Liu in
Google Scholar
PubMed
Close
,
Min Liu Department of Radiology, China-Japan Friendship Hospital, Beijing, China

Search for other papers by Min Liu in
Google Scholar
PubMed
Close
,
Zhe Chen Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Search for other papers by Zhe Chen in
Google Scholar
PubMed
Close
,
Yumei Jia Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Search for other papers by Yumei Jia in
Google Scholar
PubMed
Close
, and
Guang Wang Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Search for other papers by Guang Wang in
Google Scholar
PubMed
Close

Objective

Autoimmune thyroiditis (AIT) is the most common autoimmune thyroid disease. Longitudinal relaxation time mapping (T1-mapping) measured by MRI is a new technique for assessing interstitial fibrosis of some organs, such as heart and liver. This study aimed to evaluate the relationship between T1-mapping value and thyroid function and determine the usefulness of T1-mapping in identifying thyroid destruction in AIT patients.

Methods

This case–control study recruited 57 drug-naïve AIT patients and 17 healthy controls. All participants were given thyroid MRI, and T1-mapping values were measured using a modified look-locker inversion-recovery sequence.

Results

AIT patients had significantly higher thyroid T1-mapping values than the healthy controls (1.077 ± 177 vs 778 ± 82.9 ms; P < 0.01). A significant increase in thyroid T1-mapping values was presented along with the increased severity of thyroid dysfunction (P < 0.01). Correlation analyses showed that increased thyroid T1-mapping values were associated with higher TSH and lower FT3 and FT4 levels (TSH: r = 0.75; FT3: r = −0.47; FT4: r = −0.72; all P < 0.01). Receiver-operating characteristic curve analysis revealed a high diagnostic value of T1-mapping values for the degree of thyroid destruction (area under the curve was 0.95, 95% CI: 0.90–0.99, P < 0.01).

Conclusions

AIT patients have higher thyroid T1-mapping values than the healthy controls, and the T1-mapping values increased with the progression of thyroid dysfunction. Thyroid T1-mapping value might be a new index to quantitatively evaluate the degree of thyroid destruction in AIT patients.

Open access
Elin Kahlert Clinic of Gastroenterology and Endocrinology, University Medical Center Goettingen, Goettingen, Germany

Search for other papers by Elin Kahlert in
Google Scholar
PubMed
Close
,
Martina Blaschke Clinic of Gastroenterology and Endocrinology, University Medical Center Goettingen, Goettingen, Germany
Endokrinologikum Goettingen, Goettingen, Germany

Search for other papers by Martina Blaschke in
Google Scholar
PubMed
Close
,
Knut Brockmann Interdisciplinary Pediatric Center for Children with Developmental Disabilities and Severe Chronic Disorders, University Medical Center Goettingen, Goettingen, Germany

Search for other papers by Knut Brockmann in
Google Scholar
PubMed
Close
,
Clemens Freiberg Interdisciplinary Pediatric Center for Children with Developmental Disabilities and Severe Chronic Disorders, University Medical Center Goettingen, Goettingen, Germany

Search for other papers by Clemens Freiberg in
Google Scholar
PubMed
Close
,
Onno E Janssen Endokrinologikum Hamburg, Hamburg, Germany

Search for other papers by Onno E Janssen in
Google Scholar
PubMed
Close
,
Nikolaus Stahnke Endokrinologikum Hamburg, Hamburg, Germany

Search for other papers by Nikolaus Stahnke in
Google Scholar
PubMed
Close
,
Domenika Strik Endokrinologikum Berlin, Berlin, Germany

Search for other papers by Domenika Strik in
Google Scholar
PubMed
Close
,
Martin Merkel Endokrinologikum Hannover, Hannover, Germany

Search for other papers by Martin Merkel in
Google Scholar
PubMed
Close
,
Alexander Mann Endokrinologikum Frankfurt, Frankfurt/Main, Germany

Search for other papers by Alexander Mann in
Google Scholar
PubMed
Close
,
Klaus-Peter Liesenkötter Endokrinologikum Berlin, Berlin, Germany

Search for other papers by Klaus-Peter Liesenkötter in
Google Scholar
PubMed
Close
, and
Heide Siggelkow Clinic of Gastroenterology and Endocrinology, University Medical Center Goettingen, Goettingen, Germany
Endokrinologikum Goettingen, Goettingen, Germany

Search for other papers by Heide Siggelkow in
Google Scholar
PubMed
Close

Objective

Turner syndrome (TS) is characterized by the complete or partial loss of the second sex chromosome and associated with a wide range of clinical manifestations. We aimed to assess the medical care of adult patients with TS in Germany.

Design

Retrospective multicenter observational study.

Methods

Data were collected from medical records of 258 women with TS treated between 2001 and 2017 in five non-university endocrinologic centers in Germany.

Results

Mean age was 29.8 ± 11.6 years, mean height 152 ± 7.7 cm, and mean BMI 26.6 ± 6.3 kg/m2. The karyotype was known in 50% of patients. Information on cholesterol state, liver enzymes, and thyroid status was available in 81–98% of women with TS; autoimmune thyroiditis was diagnosed in 37%. Echocardiography was performed in 42% and cardiac MRI in 8.5%, resulting in a diagnosis of cardiovascular disorder in 28%. Data on growth hormone therapy were available for 40 patients (15%) and data concerning menarche in 157 patients (61%).

Conclusion

In 258 women with TS, retrospective analysis of healthcare data indicated that medical management was focused on endocrine manifestations. Further significant clinical features including cardiovascular disease, renal malformation, liver involvement, autoimmune diseases, hearing loss, and osteoporosis were only marginally if at all considered. Based on this evaluation and in accordance with recent guidelines, we compiled a documentation form facilitating the transition from pediatric to adult care and further medical management of TS patients. The foundation of Turner Centers in March 2019 will improve the treatment of TS women in Germany.

Open access
John E M Midgley
Search for other papers by John E M Midgley in
Google Scholar
PubMed
Close
,
Rolf Larisch North Lakes Clinical, Department of Nuclear Medicine, Medical Department I, Ruhr Center for Rare Diseases (CeSER), 20 Wheatley Avenue, Ilkley LS29 8PT, UK

Search for other papers by Rolf Larisch in
Google Scholar
PubMed
Close
,
Johannes W Dietrich North Lakes Clinical, Department of Nuclear Medicine, Medical Department I, Ruhr Center for Rare Diseases (CeSER), 20 Wheatley Avenue, Ilkley LS29 8PT, UK
North Lakes Clinical, Department of Nuclear Medicine, Medical Department I, Ruhr Center for Rare Diseases (CeSER), 20 Wheatley Avenue, Ilkley LS29 8PT, UK

Search for other papers by Johannes W Dietrich in
Google Scholar
PubMed
Close
, and
Rudolf Hoermann North Lakes Clinical, Department of Nuclear Medicine, Medical Department I, Ruhr Center for Rare Diseases (CeSER), 20 Wheatley Avenue, Ilkley LS29 8PT, UK

Search for other papers by Rudolf Hoermann in
Google Scholar
PubMed
Close

Several influences modulate biochemical responses to a weight-adjusted levothyroxine (l-T4) replacement dose. We conducted a secondary analysis of the relationship of l-T4 dose to TSH and free T3 (FT3), using a prospective observational study examining the interacting equilibria between thyroid parameters. We studied 353 patients on steady-state l-T4 replacement for autoimmune thyroiditis or after surgery for malignant or benign thyroid disease. Peripheral deiodinase activity was calculated as a measure of T4–T3 conversion efficiency. In euthyroid subjects, the median l-T4 dose was 1.3 μg/kg per day (interquartile range (IQR) 0.94,1.60). The dose was independently associated with gender, age, aetiology and deiodinase activity (all P<0.001). Comparable FT3 levels required higher l-T4 doses in the carcinoma group (n=143), even after adjusting for different TSH levels. Euthyroid athyreotic thyroid carcinoma patients (n=50) received 1.57 μg/kg per day l-T4 (IQR 1.40, 1.69), compared to 1.19 μg/kg per day (0.85,1.47) in autoimmune thyroiditis (P<0.01, n=76) and 1.08 μg/kg per day (0.82, 1.44) in patients operated on for benign disease (P< 0.01, n=80). Stratifying patients by deiodinase activity categories of <23, 23–29 and >29 nmol/s revealed an increasing FT3–FT4 dissociation; the poorest converters showed the lowest FT3 levels in spite of the highest dose and circulating FT4 (P<0.001). An l-T4-related FT3–TSH disjoint was also apparent; some patients with fully suppressed TSH failed to raise FT3 above the median level. These findings imply that thyroid hormone conversion efficiency is an important modulator of the biochemical response to l-T4; FT3 measurement may be an additional treatment target; and l-T4 dose escalation may have limited success to raise FT3 appropriately in some cases.

Open access
Yun Cai Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Search for other papers by Yun Cai in
Google Scholar
PubMed
Close
,
Jieni Yan Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Search for other papers by Jieni Yan in
Google Scholar
PubMed
Close
,
Yong Gu Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Search for other papers by Yong Gu in
Google Scholar
PubMed
Close
,
Heng Chen Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Search for other papers by Heng Chen in
Google Scholar
PubMed
Close
,
Yang Chen Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Search for other papers by Yang Chen in
Google Scholar
PubMed
Close
,
Xinyu Xu Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Search for other papers by Xinyu Xu in
Google Scholar
PubMed
Close
,
Mei Zhang Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Search for other papers by Mei Zhang in
Google Scholar
PubMed
Close
,
Liping Yu Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA

Search for other papers by Liping Yu in
Google Scholar
PubMed
Close
,
Xuqin Zheng Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Search for other papers by Xuqin Zheng in
Google Scholar
PubMed
Close
, and
Tao Yang Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Search for other papers by Tao Yang in
Google Scholar
PubMed
Close

Objective

The most common coexisting organ-specific autoimmune disease in patients with type 1 diabetes mellitus (T1DM) is autoimmune thyroid disease (AITD). However, there have been few clinical reports based on a large population about the prevalence of zinc transporter 8 autoantibody (ZnT8A) and other islet autoantibodies in AITD patients. We aimed to explore the presence of islet autoantibodies, ZnT8A, glutamic acid decarboxylase autoantibodies (GADA) and insulinoma-associated antigen 2 autoantibodies (IA-2A) compared with thyroid autoantibodies, thyroid peroxidase autoantibodies (TPOAb) and thyroglobulin autoantibodies (TGAb) and thyrotropin receptor autoantibodies (TRAb) in patients with Graves’ disease (GD), Hashimoto’s thyroiditis (HT) and T1DM patients with AITD.

Methods

Totally, 389 patients with GD, 334 patients with HT, 108 T1DM patients with AITD and 115 healthy controls (HC) were recruited in the study. Islet autoantibodies (ZnT8A, GADA and IA-2A) were detected by radioligand binding assay. Thyroid autoantibodies, TPOAb and TGAb were detected by chemiluminescence assay, and TRAb was detected by RIA.

Results

The prevalence of ZnT8A, GADA and IA-2A was higher in GD and HT patients than that of HC (ZnT8A: GD 8.48%, HT 10.8% vs HC 1.74%; GADA: GD 7.46%, HT 7.74% vs HC 0.870%; IA-2A: GD 4.88%, HT 3.59% vs HC 0%; All P < 0.05) but lower than that of T1DM subjects with AITD (ZnT8A: 42.6%; IA-2A: 44.4%; GADA: 74.1%; all P < 0.0001).

Conclusions

An increased prevalence of ZnT8A as well as GADA and IA-2A was found in both GD and HT patients, indicating that there is a potential link between thyroid autoimmunity and islet autoimmunity.

Open access
T Grimmichova Institute of Endocrinology, Narodni, Prague, Czech Republic
2nd Department of Internal Medicine, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University in Prague, Srobarova, Prague, Czech Republic

Search for other papers by T Grimmichova in
Google Scholar
PubMed
Close
,
M Haluzik Institute of Endocrinology, Narodni, Prague, Czech Republic
Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Videnska, Prague, Czech Republic

Search for other papers by M Haluzik in
Google Scholar
PubMed
Close
,
K Vondra Institute of Endocrinology, Narodni, Prague, Czech Republic

Search for other papers by K Vondra in
Google Scholar
PubMed
Close
,
P Matucha Institute of Endocrinology, Narodni, Prague, Czech Republic

Search for other papers by P Matucha in
Google Scholar
PubMed
Close
, and
M Hill Institute of Endocrinology, Narodni, Prague, Czech Republic

Search for other papers by M Hill in
Google Scholar
PubMed
Close

Objective

Patients with type 2 diabetes (T2DM) generally experience a higher incidence of cancer. However, the association between T2DM and thyroid cancer is inconclusive.

Methods

Case-control prospective study, where 722 patients were screened for T2DM and prediabetes (PDM) and underwent thyroid ultrasound and biochemical tests. The patients were assigned to groups of PDM (n = 55), T2DM (n = 79) or a non-diabetes group (NDM) (n = 588). Fine-needle aspiration biopsy was carried out in 263 patients. Histological examinations were done for 109 patients after surgery, with findings of 52 benign (BS) and 57 malignant tumors (MS).

Results

Thirty-three percent of patients with T2DM and especially PDM were newly diagnosed by our screening: 6.5% with T2DM and 72% with PDM, respectively. The percentage of thyroid cancers did not significantly differ between the groups (χ2 test = 0.461; P = 0.794). Relevant positive thyroid predictors for T2DM (t-statistic = 25.87; P < 0.01) and PDM (21.69; P < 0.01) contrary to NDM (−26.9; P < 0.01) were thyroid volume (4.79; P < 0.01), thyroid nodule volume (3.25; P < 0.01) and multinodular thyroid gland (4.83; P < 0.01), while negative relevant predictors included the occurrence of autoimmune thyroid disease (AITD) (−2.01; P < 0.05).

Conclusion

In general, we did not observe an increased risk for thyroid cancer in the diabetic and prediabetic groups in comparison to controls, in spite of well-established increased risk for other malignancies. Structural and benign changes such as larger and multinodular thyroid glands, in comparison to autoimmune thyroid disease, are present more often in diabetics.

Open access
Hauke Thomsen Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany
Center for Primary Health Care Research, Lund University, Malmö, Sweden
GeneWerk GmbH, Heidelberg, Germany

Search for other papers by Hauke Thomsen in
Google Scholar
PubMed
Close
,
Xinjun Li Center for Primary Health Care Research, Lund University, Malmö, Sweden

Search for other papers by Xinjun Li in
Google Scholar
PubMed
Close
,
Kristina Sundquist Center for Primary Health Care Research, Lund University, Malmö, Sweden
Departments of Family Medicine and Community Health, Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Center for Community-based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Shimane, Japan

Search for other papers by Kristina Sundquist in
Google Scholar
PubMed
Close
,
Jan Sundquist Center for Primary Health Care Research, Lund University, Malmö, Sweden
Departments of Family Medicine and Community Health, Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Center for Community-based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Shimane, Japan

Search for other papers by Jan Sundquist in
Google Scholar
PubMed
Close
,
Asta Försti Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany
Center for Primary Health Care Research, Lund University, Malmö, Sweden
Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany
Division of Pediatric Neurooncology, German Cancer Research Centre (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany

Search for other papers by Asta Försti in
Google Scholar
PubMed
Close
, and
Kari Hemminki Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany
Center for Primary Health Care Research, Lund University, Malmö, Sweden
Division of Cancer Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany
Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, Pilsen, Czech Republic

Search for other papers by Kari Hemminki in
Google Scholar
PubMed
Close

Design

Addison’s disease (AD) is a rare autoimmune disease (AID) of the adrenal cortex, present as an isolated AD or part of autoimmune polyendocrine syndromes (APSs) 1 and 2. Although AD patients present with a number of AID co-morbidities, population-based family studies are scarce, and we aimed to carry out an unbiased study on AD and related AIDs.

Methods

We collected data on patients diagnosed with AIDs in Swedish hospitals and calculated standardized incidence ratios (SIRs) in families for concordant AD and for other AIDs, the latter as discordant relative risks.

Results

The number of AD patients was 2852, which accounted for 0.4% of all hospitalized AIDs. A total of 62 persons (3.6%) were diagnosed with familial AD. The SIR for siblings was remarkably high, reaching 909 for singleton siblings diagnosed before age 10 years. It was 32 in those diagnosed past age 29 years and the risk for twins was 323. SIR was 9.44 for offspring of affected parents. AD was associated with 11 other AIDs, including thyroid AIDs and type 1 diabetes and some rarer AIDs such as Guillain–Barre syndrome, myasthenia gravis, polymyalgia rheumatica and Sjögren’s syndrome.

Conclusions

The familial risk for AD was very high implicating genetic etiology, which for juvenile siblings may be ascribed to APS-1. The adult part of sibling risk was probably contributed by recessive polygenic inheritance. AD was associated with many common AIDs; some of these were known co-morbidities in AD patients while some other appeared to more specific for a familial setting.

Open access